184 related articles for article (PubMed ID: 12490000)
1. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB.
Zhang Y; Yu J; Unni E; Shao TC; Nan B; Snabboon T; Kasper S; Andriani F; Denner L; Marcelli M
Hum Gene Ther; 2002 Nov; 13(17):2051-64. PubMed ID: 12490000
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
3. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.
Andriani F; Nan B; Yu J; Li X; Weigel NL; McPhaul MJ; Kasper S; Kagawa S; Fang B; Matusik RJ; Denner L; Marcelli M
J Natl Cancer Inst; 2001 Sep; 93(17):1314-24. PubMed ID: 11535706
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.
Li X; Marani M; Yu J; Nan B; Roth JA; Kagawa S; Fang B; Denner L; Marcelli M
Cancer Res; 2001 Jan; 61(1):186-91. PubMed ID: 11196158
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
8. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
Bruckheimer EM; Spurgers K; Weigel NL; Logothetis C; McDonnell TJ
J Urol; 2003 Apr; 169(4):1553-7. PubMed ID: 12629413
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
[TBL] [Abstract][Full Text] [Related]
12. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.
Hahm ER; Arlotti JA; Marynowski SW; Singh SV
Clin Cancer Res; 2008 Feb; 14(4):1248-57. PubMed ID: 18281560
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells.
Li X; Marani M; Mannucci R; Kinsey B; Andriani F; Nicoletti I; Denner L; Marcelli M
Cancer Res; 2001 Feb; 61(4):1699-706. PubMed ID: 11245486
[TBL] [Abstract][Full Text] [Related]
14. A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity.
Honda T; Kagawa S; Spurgers KB; Gjertsen BT; Roth JA; Fang B; Lowe SL; Norris JS; Meyn RE; McDonnell TJ
Cancer Biol Ther; 2002; 1(2):163-7. PubMed ID: 12170776
[TBL] [Abstract][Full Text] [Related]
15. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
16. Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines.
Ng AY; Bales W; Veltri RW
Anal Quant Cytol Histol; 2000 Feb; 22(1):45-54. PubMed ID: 10696460
[TBL] [Abstract][Full Text] [Related]
17. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
18. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.
Tai YT; Strobel T; Kufe D; Cannistra SA
Cancer Res; 1999 May; 59(9):2121-6. PubMed ID: 10232598
[TBL] [Abstract][Full Text] [Related]
19. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
